Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Valaciclovir: development, clinical utility and potential.

R Patel1

  • 1Department of Genitourinary Medicine, Royal South Hants Hospital, Southampton,Hampshire, SO9 4PE, UK.

Expert Opinion on Investigational Drugs
|February 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Involvement of PKC-iota in glioma proliferation.

Cell proliferation·2008
Same author

Evaluating the role of HLA-DQ polymorphisms on immune response to bacterial superantigens using transgenic mice.

Tissue antigens·2007
Same author

Varicella zoster virus-associated disease in adult kidney transplant recipients: incidence and risk-factor analysis.

Transplant infectious disease : an official journal of the Transplantation Society·2007
Same author

Vancomycin-resistant enterococcal colonization appears associated with increased mortality among allogeneic hematopoietic stem cell transplant recipients.

Bone marrow transplantation·2007
Same author

Nasal and nasopharyngeal lymphoma in cats: 50 cases (1989-2005).

Veterinary pathology·2007
Same author

Current management strategies for the treatment and prevention of cytomegalovirus infection in solid organ transplant recipients.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Targeting fatty acid synthase inhibitors for the treatment of acne vulgaris: what can we learn from early phase investigations.

Expert opinion on investigational drugs·2026
Same journal

Elezanumab for the treatment of spinal cord injury: assessing the clinical development journey to date.

Expert opinion on investigational drugs·2026
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
See all related articles

Valaciclovir significantly enhances aciclovir bioavailability, offering improved efficacy for herpes zoster and genital herpes simplex virus infections. This antiviral agent maintains a favorable safety profile, addressing unmet needs in anti-herpesvirus therapy.

Area of Science:

  • Pharmacology
  • Virology
  • Clinical Medicine

Background:

  • Valaciclovir is an L-valine ester prodrug of aciclovir, designed to improve oral bioavailability.
  • Current anti-herpesvirus therapies present unmet needs, particularly in efficacy and dosing frequency.
  • Aciclovir has an established safety profile for treating herpesvirus infections.

Purpose of the Study:

  • To evaluate the efficacy and safety of valaciclovir compared to aciclovir in treating herpes zoster and genital herpes simplex virus (HSV) infections.
  • To assess the pharmacokinetic profile and bioavailability of valaciclovir across various patient populations.
  • To explore the potential of valaciclovir in cytomegalovirus (CMV) prophylaxis.

Main Methods:

  • Controlled clinical trials comparing valaciclovir and aciclovir regimens.

Related Experiment Videos

  • Pharmacokinetic studies in healthy volunteers and diverse patient groups (elderly, HIV-positive, renal/hepatic impairment, transplant recipients).
  • Long-term studies evaluating safety and efficacy for HSV suppression.

    • Main Results:

    • Valaciclovir demonstrated superior efficacy in resolving zoster-associated pain and post-herpetic neuralgia compared to aciclovir.
    • Twice-daily valaciclovir was as effective as five-times-daily aciclovir for acute genital HSV treatment.
    • Patient-initiated valaciclovir therapy reduced lesion development in recurrent genital herpes; long-term suppression was effective with good tolerability.
    • Valaciclovir showed similar bioavailability across various patient populations and no significant drug interactions were identified.

    Conclusions:

    • Valaciclovir offers enhanced aciclovir bioavailability, leading to improved therapeutic outcomes for herpes zoster and genital HSV infections with less frequent dosing.
    • The drug maintains an acceptable safety profile, consistent with aciclovir, across diverse patient groups.
    • Valaciclovir presents a valuable option for managing herpesvirus infections and shows promise for CMV prophylaxis.